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Ufmylation is a post-translational modification essential for regulating key cellular processes.
A three-enzyme cascade involving E1, E2 and E3 is required for UFM1 attachment to target
proteins. How UBA5 (E1) and UFC1 (E2) cooperatively activate and transfer UFM1 is still
unclear. Here, we present the crystal structure of UFC1 bound to the C-terminus of UBA5,
revealing how UBA5 interacts with UFC1 via a short linear sequence, not observed in other E1-
E2 complexes. We find that UBA5 has a region outside the adenylation domain that is
dispensable for UFC1 binding but critical for UFM1 transfer. This region moves next to UFC1’s
active site Cys and compensates for a missing loop in UFC1, which exists in other E2s and is
needed for the transfer. Overall, our findings advance the understanding of UFM1’s con-
jugation machinery and may serve as a basis for the development of ufmylation inhibitors.
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Post-translational modifications by ubiquitin-like proteins(UBLs) are essential regulatory mechanisms ineukaryotes1–4. Ubiquitin fold modifier 1 (UFM1) is a UBL
that shares as little as 21% sequence identity with ubiquitin, but
still possesses ubiquitin’s classic β-grasp fold5,6. Modification by
UFM1 (ufmylation) is involved in regulating several cellular
processes such as the DNA damage response, the endoplasmic
reticulum stress response, cell division, erythropoiesis, and fatty
acid metabolism7–12. Impaired ufmylation leads to a range of
cellular dysfunctions and has been shown to be connected to
several human diseases including cancer and diabetes13–16.
Analogous to ubiquitination, ufmylation is carried out by a three-
enzyme cascade involving E1, E2, and E3 proteins. The E1 UBA5
has three distinct regions: (1) an adenylation domain that binds
ATP and magnesium ions; (2) a UFM1-interacting sequence
(UIS) spanning amino acids 334 to 346 that holds UFM1 in a
trans binding mechanism; and (3) a UFC1-binding sequence
(UBS) from 392 to 404 that binds UFC117–21 (Fig. 1a, b). The
process of UFM1 activation is initiated by the binding of ATP,
magnesium ions, and UFM1 to UBA5, followed by adenylation of
the C-terminal glycine of UFM1 with the release of pyropho-
sphate. The adenylated UFM1 is then subjected to a nucleophilic
attack by the catalytic C250 of UBA5 to form a thioester bond
with the C-terminal glycine of UFM1. This is followed by a trans
thiolation process, whereby the UFM1 is transferred to the E2
UFC1 forming a thioester bond with C116 of UFC1. The final
stage includes the transfer of UFM1 to the target protein via the
E3 ligase UFL122.
The mechanism of ufmylation is unique in many ways, one of
which is how UFC1 binds UBA5 in order to promote UFM1
transfer. Canonical E1 enzymes contain a ubiquitin fold domain
(UFD) that is dedicated to the interaction with the E223,24.
Similarly, in the non-canonical E1 enzyme Atg7, a specific
domain (~280 amino acids), known as the N-terminal domain
(NTD), is responsible for the interactions with the cognate
E2s25–27. However, UBA5 does not harbor such a domain but
instead has a short sequence called UBS that is responsible for the
interaction with UFC128. To date, there have been no structural
insights into how this short sequence binds UFC1 and ensures
UFM1 transfer specificity.
Here we report the crystal structure of UFC1 in complex with
the UBS of UBA5. This structure reveals that the UBS adopts a
helical conformation that interacts with UFC1, mainly via
hydrophobic interactions. UFC1 possesses a pocket, lacking in
other E2 enzymes, in which the UBS fits spatially. Moreover, we
have identified in UBA5 a region outside the UBS that is para-
mount for the transfer of UFM1. Upon UBS binding to UFC1,








































































Fig. 1 Structural characterization of the UFC1-UBS interaction. a Schematic representation of UBA5 elements. UIS (UFM1-interacting motif); UBS (UFC1-
binding sequence) b Trans-binding mechanism of UFM1 and UFC1 to the homodimeric UBA5. UFM1 and UFC1 bind the UIS and UBS, respectively, of one
molecule of UBA5 and interacts with the adenylation domain of the other UBA5 molecule. For simplicity, the UIS and UBS are shown only for one molecule
of UBA5. The black arrow indicates the linker connecting the UIS to UBS; AD-adenylation domain. c Crystal structure of UFC1 (brown) bound to UBS (red);
black arrow points on the active site Cys116 of UFC1 (yellow sphere). d Contact between UBS and UFC1 α-helix 1 and β-strand 1. Sidechains of UFC1
residues involved in UBS binding are shown in stick representation. e M401 (highlighted by yellow arrow) of UBS (red) occupies a hydrophobic pocket on
the surface of UFC1 (brown) f SDS-PAGE analysis showing the effect of UBS mutations on UFM1 transfer to UFC1. The gel is representative of two
independent experiments.
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physicochemical features of that cysteine. We found that this
region is mandatory to enable the UFC1 active site Cys to attack
and accept UFM1. Surprisingly, UFC1 lacks an essential loop
located next to the active site Cys that exists in other E2 enzymes.
Our results suggest that UBA5 contributes to this region to
compensate for the missing loop in UFC1, thereby permitting
UFM1 transfer. Overall, we have deciphered a mechanism that
guarantees UBL transfer specificity between E1 and E2 that is
based on an E2 that lacks a key element needed for the catalytic
activity that is complemented by its cognate E1.
Results
Crystal structure of the UFC1-UBS complex. To provide
structural insights into the interaction of UFC1 with the UFC1-
binding sequence (UBS) of UBA5, we determined the crystal
structure of UBA5 (389-404) fused to the C-terminus of UFC1 at
2.4 Å resolution (Supplementary Table 1). The asymmetric unit
comprises two molecules of UFC1, each interacting with a UBS
that is fused to a UFC1 molecule derived from another asym-
metric unit (Supplementary Figs. 1 and 2). The UBS forms an α-
helix and interacts with UFC1 on the side opposite to the active
site surface (Fig. 1c). The UBS residues L394, L397, M398, M401,
and M404 form hydrophobic interactions with residues V29, L32,
L39, I40, V43 of α-helix 1 and F54 and L56 of β-strand 1 of UFC1
(Fig. 1d). More specifically, M401 occupies a hydrophobic pocket
on the UFC1 surface (Fig. 1e). Accordingly, M401R and L397R
mutations in the UBS prevented the interaction with UFC1
(Supplementary Fig. 3) and damaged UFM1 transfer (Fig. 1f).
Besides hydrophobic interactions, the main chain carboxyl oxy-
gen atoms of M404 forms hydrogen bonds with the side chains of
UFC1 K47 and R55. In addition, K400 and K402 of the UBS form
salt bridges with E44 and E57 of UFC1, respectively. However,
mutations of these residues did not affect UFM1 transfer (Sup-
plementary Fig. 4), suggesting that the binding of UBS to UFC1 is
mainly mediated by hydrophobic interactions.
To date, UBA5 has been shown to transfer UFM1 to UFC1 but
not to other E2 enzymes6. Accordingly, the binding surface that is
responsible for the interaction with the UBS does not exist in
other E2 enzymes, suggesting that they are not amenable for UBS
binding. Specifically, the superposition of UFC1-UBS fused
structure with other E2s shows that the UBS suffers steric clashes
with α-helix 1, β-strand 1, and the loop connecting the strands-1
and 2 (Supplementary Fig. 5).
A UBS-independent role of the UBA5 linker. While the UBA5
construct 1–392, which lacks the UBS, significantly hampered the
transfer of UFM1, we unexpectedly found that UBA5(1–347),
which lacks not only the UBS but also the linker connecting the
UBS to the UIS, completely failed to transfer UFM1 to UFC1
(Fig. 2a). Moreover, removing this linker, but not the UBS
(UBA5Δ349–389) abolished transfer of UFM1 (Fig. 2a) but had
little effect on the binding of UFC1 to UBA5 (the measured Kd
was 5.5 μM while the one we published for the WT UBA5-UFC1
complex was 1 μM)29 (Fig. 2b). These results suggest that UBA5
amino acids 349–389 are not essential for UFC1 binding, but have
an additional role besides serving as a linker that connects the
UBS. Therefore, to further characterize the UBS-independent role
of amino acids 347–392 in UFM1 transfer, we tested UBA5
truncations for their ability to transfer UFM1. As shown in
Fig. 2a, while UBA5(1–363) failed to transfer, UBA5(1–377)
functions similarly to UBA5 (1–392). These results suggest that
residues 363–377 are indispensable for UFC1 transfer. Next, we
asked whether UBA5 residues 347–377 play a role in UFM1
transfer to another acceptor besides UFC1. Since to date, UFC1 is
the only known E2 that works with UFM1, we exploited free Cys
as a UFM1 acceptor. As shown in Fig. 2c, free Cys at a high
concentration successfully discharged UBA5 (1–347), suggesting
that residues 347–377 are critical for UFM1 transfer to UFC1 but
not to free Cys.
Next, with these results in hand, we hypothesized that residues
347–377 are required not for UBA5 but for UFC1 activity.
Specifically, if these residues are needed for UFC1 function, then
one would expect that adding them in trans would recover
transfer to some extent. Indeed, as shown in Fig. 2d, e, we
recovered the transfer of UFM1 from UBA5(1–347) to UFC1 by
adding a UBA5 fragment comprising residues 347–404. Of note,
since UBA5 fragment 347–404 does not run in SDS–PAGE
analysis as expected for a 6.4 kDa protein (Fig. 2d), we confirmed
its molecular weight in solution using SEC-MALS analysis
(Supplementary Fig. 6). Taken together our results suggest that
residues 347–377 that are critical for transfer can satisfy their role
even without being covalently linked to the UBA5 protein.
The UFC1 active site Cys is highly solvated. To elucidate how
residues 347−377 of UBA5 contribute to UFC1 activity, we asked
whether UFC1 possesses any unique feature/s that are not present
in other E2 enzymes. Initially, we calculated the buried surface
area of the E2 active site Cys (Supplementary Table 3). Surpris-
ingly, we found that C116 is highly exposed to the solvent
compared to the relatively buried catalytic cysteine in other E2
proteins. Specifically, the buried surface area of UFC1 C116 is 4%
while for other E2s this value is significantly higher (15–36%).
Similar to other E2s, UFC1 possesses a ubiquitin-conjugating
(UBC) domain30,31. However, UFC1 contains an additional
N-terminal helix (α0) which has been shown to increase protein
stability but does not affect UFM1 transfer32. Following the active
site Cys, UFC1 has an α-helix (α1-2) while in other E2s there is a
310 helix (Fig. 3a). In addition, UFC1 lacks two helices at the
C-terminus (α3 and α4). α-helix 2 (α2) of UFC1 is long and
unbroken, while in other E2s this helix is shorter (Fig. 3b, c and
Supplementary Figs. 7 and 8). In these E2s, α2 continues with a
loop that links to helix 3 (α3). This loop envelops the catalytic
cysteine, thus burying the residue in other E2s. Accordingly, as
expected for highly exposed Cys, we found that the predicted pKa
of UFC1 C116 is 8.5, a value equivalent to a free cysteine, and
~1.5 pKa units lower than all other E2s (Supplementary Table 3).
Overall, our results suggest that UFC1 possesses a highly exposed
active site Cys that has a lower pKa than the other E2s.
The UBA5 linker plays a role in UFC1 active site desolvation.
The lack of a loop next to the UFC1 active site makes the latter
heavily solvated by the electrophilic protons supplied by the
water. This causes the active site Cys to be less potent for the
nucleophilic attack, and thereby requires desolvation prior to its
nucleophilic attack33–36. This motivated us to investigate whether
UBA5 residues 347–377 play a role in UFC1 active site desolva-
tion. Initially, we asked whether we can overcome the defects in
UFM1 transfer from UBA5(1–363) by increasing the pH. Here
the idea is that elevating the pH will make the UFC1 active site
Cys a better nucleophile (the ratio of thiolate(S−) to thiol (SH)
increases). This, in turn, will allow a productive nucleophilic
attack even though the active Cys is highly solvated. Indeed, as
shown in Fig. 3d, while UBA5 1–363 failed to transfer UFM1 to
UFC1 at pH 6.5, at pH 7.5, and above transfer was detected. Of
note, we ascribe the ability of free Cys to discharge UBA5 at pH
6.5 (Fig. 2c), to its high concentration (100 mM), which increases
the availability of unsolvated free thiol to perform the nucleo-
philic attack. Accordingly, when we performed the transfer assay
with 500 μM UFC1, a 100-fold increase from the regular con-
centration, a minor transfer of UFM1 from UBA5(1−363) to
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UFC1 was observed. Taken together, our results support that
UBA5 residues 363–377 play a role in UFC1 active site Cys
desolvation.
In order to fulfill its role in UFC1 desolvation, UBA5 residues
347–377 have to reach the vicinity of the UFC1 active site.
Therefore, to gain structural insights about this region and how it
interacts with UFC1, we attempted to crystalize UFC1 in complex
with UBA5 347–404, but with no success. However, we
successfully crystallized and determined the structure of
UBA5(347–404) that is fused to the N-terminus of UFC1 to
2.65 Å resolution (Supplementary Table 1). The asymmetric unit
contains one fusion molecule, and UFC1 interacts with the UBS
that arrives from another asymmetric unit (Fig. 3e). As expected,
the interaction of the UBS with UFC1 retains the same
architecture as observed in the structure with the shorter
fragment containing only the UBS sequence (Fig. 1). In both
structures, the UBS binds to the α-1 helix and β-1 strand of
UFC1. However, for the linker connecting the UBS, we obtained
electron density for residues 382–389 but not for 347–381,
suggesting that most of the linker is mobile. V382 (the first built
residue at the N-terminus of UBA5) is 35 Å away from UFC1
C116 (Fig. 3e). While this distance is far from the active site,
UBA5 residues 381–363 can span it, thereby we cannot rule out
the possibility that the linker reaches the vicinity of UFC1 active
site Cys.
To study how the UBA5 linker plays a role in UFC1
desolvation, we analyzed the conservation score of its residues.
Using Conseq37 we found that residues G367-T373 are relatively
more conserved (Fig. 4a). Moreover, a biallelic mutation A371T
has been reported to have negative implications on ufmylation in
human brain development, leading to early onset of encephalo-
pathy in infants, further supporting the importance of that
region38. Therefore, to start understanding the role of this region
we mutated the conserved Y372. While Y372F showed transfer
comparable to wild type, Y372A or Y372E had severely decreased
ability to transfer (Fig. 4b, c), but as expected no effect on UFC1
binding (Fig. 4d). This suggests that the aromatic residue at
position 372 of UBA5 is critical for this region to be able to
desolvate the UFC1 active site.
To satisfy its role in desolvation, Y372 has to reach the active
site Cys; however, our binding experiments show that residues
349–389 are dispensable for UFC1 binding (Fig. 2b), suggesting
that the interaction of UBA5 Y372 with UFC1 is transient. To
overcome the transience of this interaction, we investigated
whether we could trap it using a disulfide bond. Since the UBA5
active site Cys should be juxtaposed with the UFC1 active site Cys
for transthiolation, we successfully obtained a disulfide bond
between UBA5 WT and UFC1 active site Cys residues (we used
DPDS to facilitate disulfide bond formation; see Method section)
(Fig. 4e). Accordingly, UBA5 with a C250A mutation, although
comprising 7 cysteine residues in its sequence, failed to form a
disulfide bond with UFC1. However, the double mutant C250A
and A371C recovered the disulfide bond with UFC1, suggesting
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Fig. 2 The UBS independent role of the linker connecting the UBS to UIS. a SDS–PAGE analysis showing the effect of UBA5 truncations or deletion on the
transfer of UFM1 to UFC1. The gel is representative of at least two independent experiments. b ITC experiment of UFC1 binding to UBA5 Δ349−389. The
top graph represents raw data of heat flow versus time. The area under the peaks of the upper panel was integrated and plotted as kcal per mole of UFC1 as
a function of binding stoichiometry in the bottom panel. Thermodynamic parameters are summarized in Supplementary Table 2. c SDS–PAGE analysis
showing the discharge of UBA5WT or (1–347) by free cysteine (100mM). The gel is representative of at least two independent experiments. d SDS-PAGE
analysis showing the effect of UBA5(347–404) on the transfer of UFM1 to UFC1 from UBA5(1–347). e Three independent experiments as shown in d were
performed to quantify the effect of adding the UBA5 fragment in trans on UFM1 transfer to UFC1. Data are represented by mean ± SD.
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active site Cys (Fig. 4e). Next, to further support the idea that
A371 reaches the active site, we investigated whether we can
charge UFM1 on UFC1, employing UBA5 with the double
mutation C250A and A371C. Specifically, since UBA5 residue
371 is next to the active site of UFC1, we expected that UFC1 will
be able to accept UFM1 from UBA5 that is charged with UFM1
on C371. Indeed, as shown in Fig. 4f, while UBA5 C250A, as
expected, failed to activate UFM1, UBA5 double mutant C250A
and A371C recovered UFM1 transfer to UFC1, providing further
support that it reaches the vicinity of active site cysteine. Taken
together, our results suggest that the linker of UBA5 comprising
residues 363-377 reaches the environment of the UFC1 active site
Cys, and this probably plays a role in desolvation.
The need for an aromatic residue at position 372 of UBA5 to
satisfy UFM1 transfer to UFC1 led us to hypothesize that this
residue is involved in a π–π stacking interaction. To explore this
possibility, we looked for UFC1 aromatic residues that are next to
the active site Cys and are capable of this mode of interaction.
UFC1 Y110 is located on the surface, highly exposed, and at a
hydrogen-bonding distance from the thiol of C116. We first
tested whether the Y110F mutation, which keeps that aromatic
ring but cannot form a hydrogen bond with C116, has any effect
on UFM1 transfer. As shown in Fig. 5a, b, Y110F showed no
defect in transfer, indicating that the role of this residue does not
depend on hydrogen bonding with the active site Cys. Similarly,
UBC9 that comprises Y87 at the same position as UFC1 Y110 is
not involved in hydrogen bonding with the active site Cys (PDB
1U9A). However, when we mutated Y110 to Ala a 50% decrease
in UFM1 transfer was observed (Fig. 5a, b), supporting the need
for an aromatic residue at that position.
To gain structural insights into the interaction of UBA5 Y372
with UFC1 Y110, we used the Rosetta FlexPepDock peptide
docking protocol39 to model UFC1 bound to a peptide
comprising UBA5 residues 370–377 (starting with blind, global
docking, followed by refinement of conformations near the active
site; see “Methods” section for more details). Our results
converged into 2 distinct conformations of the peptide among
the top-scoring models: While the conformation of the peptide
C-terminal region (around K377) was homogeneous, the
N-terminal part (around V370) showed a larger variance covering
d
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Fig. 3 UFC1 lacks a structural loop adjacent to the active site Cys. a. Topology depictions of UFC1 (orange) and UBC9 (blue) secondary structure
elements. b Superposition of UFC1 (orange) with UBC9 (blue). Helices are numbered as shown in a. Active site Cys residues of UBC9 and UFC1 are in stick
representation. c Superposition of UFC1 (surface representation) with seven different E2s (UBCH5b (3TGD), UBC9 (5F6E), UBC13 (1J7D), UBCH5c (1X23),
E2E2 (1Y6L), UBCH7 (4Q5E), UBCH10 (4YII)) in cartoon representation. E2s are colored as shown in Supplementary Fig. 7. The yellow dot indicates the
position of the active site Cys. d SDS−PAGE analysis showing the effect of pH on UFM1 transfer to UFC1 from UBA5 1–363. The gel is representative of at
least two independent experiments. e Crystal structure of UFC1 fused to UBA5 residues comprising the linker and UBS (347–404). The figure shows two
molecules while the UBS of the red molecule interacts with the UFC1 that arrives from the yellow molecule. Residues 347–381 of UBA5, although present in
the crystal, are not shown in the structure due to a lack of electron density.
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the UFC1 interface. In one conformation, UBA5 residue Y372 is
closely stacked against UFC1 Y110 (Fig. 5c), supporting π-π
stacking interaction. In the second conformation (Fig. 5c), Y372
enters a cavity on UFC1’s surface and points towards UFC1 F121.
Indeed, F121A mutation harmed UFM1 transfer, similarly to the
Y110A mutation, and a double mutant hardly showed transfer
(Fig. 5a, b). However, when we increased the pH to 8.5, an
improvement in the transfer was observed (Fig. 5d, e), suggesting
that these mutations are not structural mutations but rather
perturb the ability of UBA5 residues 363–377 to reach the active
site and fulfill their role in desolvation.
To further understand how the UFC1 double mutant (Y110A
and F121A) affects UFM1 transfer to UFC1, we determined its
crystal structure to 2.2 Å resolution (Supplementary Table 1). As
expected, the double mutant kept the overall UBC fold as
observed in WT UFC1 with an RMSD of 0.3 Å2. The main
differences were concentrated in the loop harboring the active site
Cys (Fig. 5f). Specifically, Leu 117 Cα moves 1.7 Å away from its
position in the WT, and its side chain points towards the position
of the missing phenylalanine (F121A). This movement is not
feasible in the WT due to steric clashes with F121.
Then, to understand how these conformational changes affect
UFM1 transfer, we examined our model suggesting that UBA5
Y372 utilizes a cavity on the UFC1 surface (Fig. 5c). To that end,
we measured the volume of this cavity in UFC1 WT and double
mutant using CASTp40. While in WT this cavity has a volume of
377 Å3, in the double mutant it becomes 126 Å3 (Fig. 5g). This
change probably hampers the ability of UBA5 Y372 to occupy
this pocket and therefore affects the recruitment of UBA5 linker
to the active site Cys. Interestingly, in other E2 enzymes whose
active site Cys is less exposed and therefore do not need this
mechanism of E1-mediated desolvation, the corresponding cavity
is significantly smaller or does not exist (Supplementary Table 4).
Notably, unlike UFC1 which has the helix (α1-2), other E2s have
a shorter 310 helix (Fig. 3a) that occludes the space between itself
and helix 2, thereby not making room for a cavity or for only a
significantly smaller one. Taken together, our results suggest that
changes in the cavity volume of UFC1 due to the double mutant
interferes with the ability of UBA5 to execute its role in
desolvation, and accordingly, increasing the pH helps to
overcome the defect in transfer.
For the desolvation, the UBA5 linker has to reach next to
UFC1 active site. This prompted us to use NMR spectroscopy to
define the chemical shift perturbations around UFC1 active site
Cys upon binding of the linker. The reported assigned (1H, 15N)-
HSQC NMR spectra for UFC141 enables probing interactions of
UFC1 at the residue level. The addition of a UBA5 fragment
possessing the linker together with the UBS (residues 347–404) to
15N-labeled UFC1 caused strong attenuations at an intermediate-
slow exchange on the NMR chemical shift timescale, in
agreement with our determined KD of 1 μM (Fig. 6a and
Supplementary Fig. 9). On the other hand, as expected, the
interaction of UFC1 with UBA5 linker alone (residues 347–392)
was significantly weaker, with changes occurring purely in the fast
exchange regime (Fig. 6b and Supplementary Fig. 9). In line with
the crystal structure of the UBA5-UBS complex, only the
fragment possessing the UBS (i.e., 347–404) generated chemical
perturbations in UFC1 residues that are involved in UBS binding
(Fig. 6c). Both fragments perturbed residues at the N-terminal
helix of UFC1 (α0) (Fig. 6a, b). Interestingly, this helix is not part
of the canonical UBC fold and is missing in other E2s (Fig. 3a).
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Fig. 4 Characterization of UBA5 linker. a ConSeq evolutionary conservation analysis of UBA5(351–390). b SDS–PAGE analysis showing the effect of Y372
mutations on the transfer of UFM1 to UFC1. c Three independent experiments as shown in b were performed to quantify the effect of the indicated
mutations on UFM1 transfer. Data are represented by mean ± SD. d ITC experiment of UFC1 binding to UBA5 Y372A. The top graph represents raw data of
heat flow versus time. The area under the peaks of the upper panel was integrated and plotted as kcal per mole of UFC1 as a function of binding
stoichiometry in the bottom panel. Thermodynamic parameters are summarized in Supplementary Table 2. e UBA5 WT or mutants were incubated with
UFC1 that was activated with DPDS and then were subjected to SDS PAGE analysis for UBA5-UFC1 adduct formation. The gel is representative of two
independent experiments. f UBA5 WT or mutants were incubated with WT UFC1 and UFM1 then subjected to SDS–PAGE analysis for the formation of
UFM1 charged UFC1. The gel is representative of two independent experiments.
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thermal stability to UFC1 may have an additional role in UFM1
transfer. Besides the N-terminal helix, the UFC1 helix (α1-2),
which follows the active site Cys and exists as a short 310 helix in
other E2s, showed significant chemical perturbations with both
fragments. These chemical perturbations include F121, which
resides on that helix and based on our structural model
approaches next to Y372 of the linker (Fig. 5c). UFC1 Y110,
which is 3.5 Å from the active site Cys and possibly interacts with
Y372 of the linker (Fig. 5c) is missing in the CSP analysis since it
could not be assigned in our NMR experiments. However,
chemical perturbation of UFC1 active site C116 was clearly
observed in the presence of the fragment possessing the UBS
(Fig. 6a). Overall, the NMR data support our model suggesting
that the presence of the UBA5 linker alters the chemical
environment of the active site Cys.
Ultimately, we aimed to assess the UBS-UFC1 structure in the
context of the intact complex comprising UBA5~UFM1 and
UFC1. Previously we showed that UFM1 binds UBA5 in a trans-
binding mechanism20. In this mode of binding, UFM1 binds the
UIS of one UBA5 molecule and forms a thioester bond with the
active site Cys of the other UBA5 molecule in the dimeric UBA5
(Fig. 1b). Similarly, we found that UFC1 binds the UBS of one
UBA5 molecule and receives UFM1 that is linked to the active site
Cys of the other molecule20. With these data in mind, we initially
docked UFC1 (PDB 2Z6P) to UBA5-UFM1 (PDB 6H77), keeping
the active site Cys of UBA5 and UFC1 next to each other. We
then superimposed the structure UFC1-UBA5(389–404) onto the
complex, showing that the binding of UBS to UFC1 does not
block the UFC1 active site Cys from reaching the UBA5 active
site (Fig. 7a). Finally, we asked whether in this ternary model
A371 can reach the active site Cys as suggested by our
biochemical data (Fig. 4e, f). Indeed, UFC1 active site Cys is
35 Å away from UBA5 amino acid 346, which is the last residue
of the UIS. This distance can easily be filled by the 25 amino acids
between residues 347–371. Accordingly, C116 is 40 Å from G391,
the first residue of the UBS, a distance that can be filled by the
missing 20 amino acids (390–371). Taken together, the trans
binding mechanism of UFM1 and UFC1 to UBA5 is in line with
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Fig. 5 Aromatic residues are involved in UFC1 desolvation. a SDS–PAGE analysis showing the effect of UFC1 mutations on the transfer of UFM1 to UFC1. b
Three independent experiments as shown in A were performed to quantify the effect of the indicated mutations on UFM1 transfer. Data are represented by
mean ± SD. c Structural model of the two main conformations (blue and cyan) of UBA5 residues 370-377 bound to UFC1. UBA5 Y372 side chain is shown
in stick representation. d SDS–PAGE analysis showing the effect of pH on UFM1 transfer to UFC1 WT or mutant. e Three independent experiments as
shown in d were performed to quantify the effect of the indicated mutations on UFM1 transfer. Data are represented by mean ± SD. f Superposition of UFC1
WT (orange) and UFC1 double mutant Y110A and F121A (blue). g Surface representation of UFC1 WT (orange) and double mutant (blue). The UFC1
residues that define the cavity are colored in cyan and red for WT and double mutant, respectively. Active site Cys is shown in yellow.
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The above ternary model proposes that UFC1 contacts the
adenylation domain of both subunits of the dimeric UBA5 (Fig. 7a).
One adenylation domain (shown in cartoon representation in
Fig. 7a), whose active site Cys approaches the vicinity of UFC1 active
site Cys, interacts with UFC1 mainly via the crossover loop. This
loop harbors the active site C250 of UBA5 and as we have previously
shown undergoes conformational changes upon charging of UBA5
with UFM120. We expect that the interaction of UFC1 with that
loop will also lead to conformational changes that are yet not clear.
Specifically, the current conformation of the UBA5 crossover in our
model prevents UFC1 active site Cys to reach a distance amenable
for nucleophilic attack on the active site Cys of UBA5. The other
adenylation domain (colored red in Fig. 7a) interacts via its
N-terminus with UFC1 helix 1–2 and the loop connecting β-strands
3 and 4. As expected, the interaction of UFC1 with both adenylation
domains is transient. Indeed, a binding experiment of UFC1 to
UBA5 lacking the adenylation domain (UBA5 333–404) yielded a
Kd that is similar to the WT protein (Fig. 7b), supporting the idea
that the main region in UBA5 that is responsible for the interaction
with UFC1 is outside the adenylation domain.
Discussion
With several E1 and many E2 enzymes in the cell, the binding
specificity of an E1 to its cognate E2 is crucial for the Ub/UBL
conjugation process. Here we provide structural insights into the
elements responsible for the binding specificity of UBA5 to
UFC1. Our structures reveal that the UBS of UBA5 binds a
unique pocket on the surface of UFC1, not existing in other E2s.
This hydrophobic pocket is located on the other side of the active
site Cys and comprises residues from α-helix 1 and β-strand 1 of
UFC1. Of note, in canonical E1 enzymes a dedicated domain, the
UFD, plays a role in E2 binding, and similarly to the UBS
interacts with α-helix I of the UBC fold42. This binding of UFC1
to the UBS, in turn, brings the UBA5 active site Cys next to UFC1
active site, thereby allowing transfer of UFM1 to UFC1. Never-
theless, the UBS does not have a catalytic role in UFM1 transfer,
as indicated by our ability to recover UFM1 transfer from UBA5
fragment lacking the UBS by increasing UFC1 protein con-
centration, supporting an affinity role.
While all E1 enzymes play the same role i.e., Ub/UBL activa-
tion and transfer to E2, UBA5 is significantly smaller in size than
other E1 enzymes42. Accordingly, UBA5 uses a short linear
sequence (UBS) for UFC1 binding while all other E1s have a
domain dedicated to E2 interaction. So far, the use of a short
sequence for E1–E2 interaction has been shown only from the E2
end. In detail, the E2s of the UBL NEDD8, UBE2M and UBE2F
have a short sequence at their N-terminus that interacts with the
heterodimeric E1, APPBP1-UBA343. Currently, it is unknown
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Fig. 6 UBA5 linker affecting UFC1 active site Cys. a–b Chemical shift perturbations (CSPs) of 0.2 mM 15N-labeled UFC1 upon addition of equimolar
concentration of UBA5347–404 (a) or five molar equivalents of UBA5347-392 (b). Bars correspond to UFC1 active site C116 and F121 are colored in red. Select
regions of 1H–15N HSQC spectra showing the spectrum of 0.2 mM UFC1 alone (black) and in the presence of an equimolar concentration of UBA5347-404
(red; a, bottom row) or five-fold excess of UBA5347-392 (purple; b, bottom row) c Structure of UFC1 (pdb 2Z6P) with the residues displaying significant
CSPs (>0.04 ppm) upon interaction with UBA5347-404 (upper panel) or UBA5347-392 (>0.008 ppm; lower panel) colored in light red. For upper panel
residues with CSPs value greater than 0.08 ppm are highlighted in red. Yellow and black arrows indicate the positions of UFC1 active site C116, or UFC1
F121, respectively.
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However, our structure reveals that UFC1 Y36, a known phos-
phorylation site44, is located at the UBS binding interface, raising
the possibility that the UFC1-UBA5 interaction can be modulated
by phosphorylation.
Over the last few years, the number of reports connecting
ufmylation to human diseases has significantly increased, high-
lighting the need for developing tools allowing specific inter-






















Fig. 7 The role of UBA5 in UFM1 transfer to UFC1. a Structural model of UBA5~UFM1 bound to UFC1. One molecule of the dimeric UBA5 is shown in
surface representation (red) and the other molecule in cartoon representation (light red). UFC1 active site Cys is colored yellow and UBA5 active site C250
that approaches next to UFC1 active site is in yellow stick representation. For simplicity, the complex has only one molecule of UFC1 and the UBA5
molecule that is shown in cartoon representation has only the adenylation domain. b ITC experiment of UFC1 binding to UBA5 333-404. The top graph
represents raw data of heat flow versus time. The area under the peaks of the upper panel was integrated and plotted as kcal per mole of UFC1 as a
function of binding stoichiometry in the bottom panel. Thermodynamic parameters are summarized in Supplementary Table 2. c UBA5 linker plays a role in
UFC1 active site Cys desolvation. The highly exposed UFC1 active site is heavily solvated by water molecules thereby reducing its nucleophilic activity.
Upon binding of UBA5 via the UBS the linker approaches to UFC1 active site Cys. This reduces the amount of water molecules in the vicinity of the active
site Cys and thereby elevates the latter’s nucleophilic activity. In other E2s the role of the linker is executed by the loop connecting helices 2 and 3 that are
missing in UFC1.
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with catalytic Cys, developing drugs that target the active site Cys
of a specific enzyme is very challenging and can lead to a non-
specific drug. Therefore, targeting additional regions on these
enzymes that are unique for a specific E1 or E2 is of high interest.
From that perspective, the unique mode of interaction of UBA5
and UFC1 that is mediated via the UBS can serve as a potential
target for specific intervention with ufmylation. Specifically,
developing peptides or small molecules that bind the UBS and
prevent interaction with UFC1 could serve as specific inhibitors
of ufmylation. In addition, the identified unique cavity above the
active site cysteine that we propose binds Y372 of UBA5, can also
serve as a potential target for developing inhibitors for
ufmylation.
As noted, in contrast to other E2s, UFC1 helix 2 is longer and
unbroken, causing the active site Cys to be missing a loop in its
vicinity. Interestingly, sequence analysis of helix 2 cannot explain
why this helix breaks in other E2s but not in UFC1. Specifically,
although helix 2 in UFC1 harbors two proline residues (P144,
P151), it keeps the helical structure unbroken. However, the
superposition of UFC1 with UBC9 shows that a longer helix 2 in
UBC9, as in UFC1, will clash with the loop connecting β-strand 2
and 3. Indeed, the superposition of E2 enzymes shows that UFC1
has a shorter loop than the other E2s. This suggests that in other
E2s helix 2 breaks due to structural elements that prevent an
elongated helix as seen in UFC1. How UFC1 binds the E3 ligase
UFL1 is still not clear. The latter does not share any similarities
with HECT or RING E3 ligases, thereby raising the question of
whether the unbroken helix 2 is needed for UFC1 to function
with UFL1.
UEV1a is a non-functional E2 that works together with the E2
UBE2N (Ubc13). Specifically, it binds UBE2N and holds the
acceptor ubiquitin in a way that directs K63 to the thioester of
UBE2N~Ub, thereby enforcing the building of K63-linked ubi-
quitin chains45,46. Unexpectedly, similar to UFC1, UEV1a ends
with helix 2, thereby lacking helices 3 and 4 that exist in other E2
enzymes. This raises the question of whether UFC1 can play a
similar role as UEV1a and acts together with a currently uni-
dentified enzyme in order to build UFM1-chains. Indeed, the
existence of K69-linked UFM1 chains has been reported but
whether in that case UFC1 functions with another partner is not
yet clear14.
Following interaction with the E1, the E2 active site Cys has to
attack the C-terminal carbonyl of Ub/UBL, breaking the thioester
bond with the E1 (E1~Ub/UBL) and generating a thioester bond
with the E2 (E2~Ub/UBL). This implies that the E2 active site has
to be able to execute the nucleophilic attack upon binding the E1
but must not react promiscuously, which would be devastating
for the cell. Previously, Tolbert et al. have suggested that the
elevated pKa of E2s’ active site Cys (~10) compared to free Cys
(~8.5) is used to control reactivity and prevent promiscuous
attacks47. However, here we surprisingly found that the pKa of
UFC1 is significantly lower than that of other E2 enzymes, sug-
gesting that the reactivity of UFC1 is not regulated by elevating its
pKa. In contrast to ubiquitin and other UBLs that share a Di-Gly
signature at the C-terminus, UFM1 ends with a Val-Gly motif.
Whether Val instead of Gly challenges the nucleophilic attack
thereby requiring a lower pKa for UFC1 active site Cys, which
would make the latter more active, is not yet clear.
In line with its relatively low pKa, UFC1 is highly exposed to
solvent compared to other E2s. While an exposed active site can
benefit accessibility to substrates, it also imposes restrictions on
its chemical reactivity. Specifically, the solvation of a nucleophile
significantly hampers its ability to attack due to interactions with
the solvent. To allow a nucleophilic attack, the highly solvated
active site Cys has to undergo desolvation. In other E2s we ascribe
the active site desolvation to a loop nearby the active site that is
missing in UFC1. This loop increases the buried surface area of
the active site Cys, thus playing a role in desolvation. Here, we
propose that in UFC1 the active site desolvation is executed by
UBA5 that brings a loop next to the UFC1 active site Cys, thereby
mimicking the role of the missing loop in UFC1 (Fig. 7c). This
UBA5 loop, which connects the UIS to UBS, includes Y372 that
occupies a cavity between Y110 and F121 of UFC1. The unper-
turbed UFM1 transfer process, irrespective of whether there is
tyrosine or phenylalanine in the place of Y372 or Y110 of UBA5
and UFC1, respectively, suggests the essentiality of the aromatic
ring rather than the hydroxyl side chain. The lesser importance of
the hydroxyl group is further supported by the observation made
by Yunis and Lima, regarding the UBC9 system, where they have
shown that there is no perturbation in the transfer process when
Y87 is mutated to phenylalanine48. Notably, the equivalent cavity
in other E2s is highly shrunken further emphasizing that the
mechanism is unique to UFC1. The coming together of three
aromatic residues assists in anchoring UBA5 residues 363-377
next to the active site Cys and allows desolvation.
Taken together, ensuring binding specificity to the right E1 and
controlled nucleophilic activity are two parameters critical for the
proper functioning of E2 enzymes. Here we found the structural
basis for how UBA5 gains its binding specificity to UFC1 via a
short linear sequence located at the C-terminus. In parallel, UFC1
uses a previously unknown mechanism to regulate its nucleo-
philic activity. Specifically, UFC1 lacks a key structural element
that is needed for its activity and is contributed by UBA5.
Methods
Cloning and mutagenesis. Human UBA5 and UFM1 were cloned into pET15b
and UFC1 was cloned into pET32a as previously described20. A UFC1 construct
called UFC1-NC was generated by mutating C69 and C165 to serine leaving only
the active site C116. In UBA5(Δ349-389) the missing residues were replaced by a
short sequence of GSG. The fusion constructs UFC1-UBA5(389-404) and
UBA5(347-404)-UFC1 were generated using Gibson assembly (Gibson assembly
master mix, New England Biolabs) according to the manufacturer’s protocol. The
point mutants of UBA5 and UFC1 were generated by Pfu Ultra II Fusion HS DNA
polymerase, an upgraded fusion polymerase technology developed by Agilent.
Protein expression and purification. All the proteins of UBA5, UFC1, and UFM1
that include fusion constructs, truncations, and point mutants were expressed as
previously described20. Escherichia coli T7 express (New England Biolabs)
expression strains were used to express all the proteins. The transformed cells were
grown in 2xYT and induced at 16 °C overnight with 0.3 mM isopropyl-β-thio-
galactoside (IPTG) (T-Fischer BioReagents). For NMR experiments the UFC1
transformed cells were grown in standard M9 minimal media supplemented with
15NH4Cl and induced at 20 °C overnight with 0.3 mM IPTG. The induced cells
were harvested by centrifugation at 29,097×g for 90 min. The proteins were purified
following a standardized protocol described earlier20. Further purification was done
using 16/60 Superdex 75 pg or 16/60 Superdex 200 pg size exclusion chromato-
graphy as applicable, equilibrated in buffer containing Tris pH 7.5 (20 mM), NaCl
(50 mM), and DTT (2 mM). The purified proteins were concentrated and flash-
frozen in liquid N2 and stored at −80 °C.
In vitro thioester assay
UBA5 activation and transfer to UFC1. UBA5 (1 μM), UFM1 (10 μM), and UFC1
(5 μM) were mixed together in a buffer containing Bis-Tris (50 mM pH6.5), NaCl
(100 mM) and MgCl2 (10 mM). For the reaction conducted in basic pH, Bis-Tris
was replaced with HEPES (50 mM) of pH 7.0, 7.5, and 8.0. For pH 8.5, the buffer
was Tris-HCl (50 mM). The concentration of the proteins was the same for all
reactions involving point mutants and truncations unless specified. Reactions were
initiated by the addition of ATP (5 mM) and were incubated at 30°C. A sample of
the reaction was removed and quenched with SDS sample buffer supplemented
with or without β-mercaptoethanol. Before activation, a sample of the reaction mix
was collected as the control at time 0. The samples collected at various time points
as required along with the control were then loaded on 12% Bis-Tris non-reducing
SDS-PAGE and visualized by Coomassie brilliant blue R staining.
Trans addition of UBA5 C-terminus to UBA5 1-347. The C-terminus of UBA5 347
to 404 (60 μM) was added to rescue the loss of function of UBA5 1–347. The
concentrations of the proteins were as described in the above paragraph. Reactions
were initiated by the addition of ATP (5 mM) and were incubated at 30 °C. The
samples were collected twice, after 30 min and after 1 h. The reaction was quenched
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with SDS sample buffer without BME. Before the addition of ATP, a sample of the
reaction mix was collected as a control. The samples were then loaded on 12% Bis-
Tris non-reducing SDS-PAGE and visualized by Coomassie brilliant blue R
staining.
Free cysteine discharge assay. UBA5 1–347 (1 μM) and UFM1(10 μM) were
mixed together in a buffer containing Bis-Tris (50 mM pH 6.5), NaCl (100 mM),
and MgCl2 (10 mM). Another reaction employing UBA5-WT was carried out in
parallel as a control. A sample of the reaction mixture was collected before the start
of the reaction. Reactions were initiated by the addition of ATP (5 mM) and were
incubated at 30 °C. Two samples of the reaction mixture were collected after 10 min
incubation and quenched with SDS sample buffer with and without β-
Mercaptoethanol. Subsequently, free cysteine (100 mM) was added to the reaction
mixture and incubated at 30 °C. A sample of the reaction mix was collected after
10 min and quenched with SDS sample buffer without β-Mercaptoethanol. The
samples were then loaded on 12% Bis-Tris non-reducing SDS-PAGE and visualized
by Coomassie brilliant blue R staining.
Isothermal titration calorimetry (ITC). Experiments were carried out on a
MicroCal PEAQ ITC system (Malvern Instruments, Malvern) at 25 °C. The
binding experiments of UBA5(Δ349–389), and point mutants UBA5 M401R,
L397R, and Y372A to UFC1-WT were conducted in buffer containing Tris
(20 mM pH 7.5), NaCl (50 mM), and DTT (2 mM). Measurements were obtained
from 19 injections where each injection is 2 μl. The data were fitted to the two sets
of sites model already built into the MicoCal PEAQ ITC analysis software. The
initial injection volume in all experiments was 0.4 μl with a duration of 0.8 s. Data
for the first injection were not considered in any experiments.
Crosslinking of UFC1-NC with UBA5 constructs. UFC1-NC was activated with
the crosslinker compound 2,2’ dithiodipyridyldisulfide (DPDS) as described23. The
protein was desalted to remove DTT present in the storage buffer. About 100–200 μM
of UFC1-NC were treated with 2.5mM of the crosslinker and incubated at 25 °C for
30min. Then, the activated UFC1-NC was desalted to remove the excess crosslinker.
Activated UFC1-NC (4 μM) was mixed with 2 μM of UBA5 (WT or mutants) in PBS
buffer at 25 °C for 20min. A sample of the reaction mix was removed and quenched
with SDS sample buffer without β-mercaptoethanol and loaded on 12% Bis-Tris non-
reducing SDS-PAGE and visualized by Coomassie brilliant blue R staining.
Crystallization. All crystals were grown at 20 °C using the hanging drop vapor
diffusion method. UFC1-UBA5(389-404) protein was concentrated to 15 mg/ml
and crystallized in the solution containing 35 mM citric acid, 65 mM bis-tris
propane, 19% PEG3350, 100 mM lithium chloride. The quality of the crystals was
improved by including lithium chloride as an additive. The crystals were soaked in
a 30% glycerol cryo mixture and flash-frozen in liquid nitrogen. UBA5(347–404)-
UFC1 at concentration of 34 mg/ml was crystallized in the solution containing 2%
(v/v) tacsimate pH 7.0, 20% PEG 3350, 0.1 M HEPES pH 7.5, 6 mM zinc sulfate.
The crystals appeared after 2 days and grew to a considerable size in 4 days. The
crystals were cryo-protected using a paraffin-paratone mixture and flash-frozen in
liquid nitrogen. UFC1 Y110A and F121A double mutant at a concentration of
12 mg/ml was crystallized in a solution containing 0.1 M Hepes pH 7.5 and 2M
ammonium sulfate. The crystals appeared within 24 h. The crystals were cryo-
protected using 18% glycerol.
X-ray data collection and processing. The diffraction data for the UFC1-
UBA5(389-404) were collected at the European Synchrotron Radiation Facility on
beamline ESRF ID23 at 100 K in a stream of gaseous nitrogen. Data were processed
using XDS49. The orthorhombic data demonstrated strong anisotropy and were
therefore subjected to anisotropic ellipsoidal truncation using the STARANISO
server50 (Supplementary Table 1). UBA5(347-404)-UFC1 data were collected on
beamline BL14.1 of BESSY-II synchrotron at 100 K. Data were processed using
XDS (Supplementary Table 1). UFC1 Y110A and F121A diffraction data were
collected on XtalLab Pro (Rigaku) with a PILATUS 200K detector. Data were
processed using HKL 3000 suite (Supplementary Table 1).
Structure determination. The structure of the UFC1-UBA5(389–404) protein was
solved by molecular replacement method (MR) with MOLREP51 using a high-
resolution structure of UFC1 (PDB 2Z6O)32. The asymmetric unit contained two
monomers of the fusion protein. The partial model was initially refined in
REFMAC552 and electron density maps were inspected in COOT53. Helical dif-
ference density was observed close to the same regions of both monomers of UFC1.
Phased molecular replacement in MOLREP54 positioned a ten-residue ideal α-
helical polyalanine fragment into the observed density. To assign side chains of the
UBA5 fragment, the electron density was averaged using DM55 and the model was
refined in REFMAC5 with input density modification phases56. In addition, the
model was subjected to refinement in BUSTER57. The resulting maps allowed
confident assignment of the protein sequence for the UBA5 fragment.
The structure of UBA5(347–404)-UFC1 was solved by the MR method
implemented in MOLREP using the solved structure of UFC1-UBA5(389–404).
The model was refined in REFMAC5 and subsequently remodeled in COOT. Multi
crystal averaging using the UBA5(347–404)-UFC1 map with the map of the high-
resolution native UFC1 structure was performed using DMMULTI55. The structure
was refined in both BUSTER and REFMAC5 with averaged phases. The electron
density maps confirmed amino acid assignment for stretch 389–404 and
additionally allowed to build backward the model of the UBA5 fragment up to
Val382 in COOT. The residues from 347 to 381 of the UBA5 fragment were not
built due to the lack of interpretable electron density. The structure of UFC1
Y110A and F121A was solved by the MR method implemented in the PhaserMR
module of CCP4 suite58 using the native UFC1 structure (PDB 2Z6P). The model
was refined in REFMAC5 and subsequently remodeled in COOT.
NMR spectroscopy. All NMR experiments were carried out at 25 °C on a 23.5 T
(1000 MHz) Bruker spectrometer equipped with a triple resonance (x,y,z) gradient
cryoprobe. The experiments were processed with NMRPipe59 and analyzed with
NMRFAM-SPARKY60.
The interaction of UFC1 with UBA5 fragments was monitored by 2D 1H–15N
HSQC experiments with the assignments for UFC1 transferred from the BMRB
(entry 6546). UBA5347–404 (50–200 μM) or UBA5347–392 (0.4–1.6 mM) were
titrated into 200 μM of 15N-labeled UFC1 in 50 mM HEPES pH 7.0, 50 mM KCl,
1 mM DTT, 0.03% NaN3, and 10% D2O and chemical shifts were recorded.









where ΔδH is the amide proton chemical shift difference and ΔδN is the 15N
backbone chemical shift difference. CSPs measured with UBA5347-404 and
UBA5347-392 fragments were considered significant if greater than half standard
deviation from the mean (>0.04 ppm or >0.008 ppm, respectively), with residues
displaying CSPs greater than 0.2 excluded from the mean calculations.
Theoretical estimation of pKa of the catalytic cysteine. The theoretical pKa and
the buried surface area of the active site cysteine residue in all the E2 proteins
including UFC1 were estimated using the PDB2PQR module in Applied Poisson
Boltzmann Server (APBS)61. The server estimates the continuum electrostatics for
large biomolecular assemblage using the Poisson-Boltzmann equation. The coor-
dinates of the protein structure after removing the solvents and water molecules
were uploaded to the server.
Ternary complex model. The structure of UFC1-UBA5(389–404) was docked to
UBA5-UFM1 structure (PDB 6H77) using Patchdock62. The UBA5-UFM1 struc-
ture was used as the receptor while the UFC1-UBA5(389–404) fused structure was
used as the ligand. A distance constraint of 5 Å between C116 of UFC1 and C250 of
UBA5 was applied for docking. The receptor-binding site parameter file constitutes
5 residues upstream and 5 residues downstream of C250 of UBA5. Likewise, the
ligand-binding site parameter file constitutes UFC1 residues from Y110 to H120,
including C116.
Docking of UBA5 linker to UFC1 using Rosetta FlexPepDock peptide docking.
Global docking with no prior information about the peptide conformation and the
exact binding site was performed using the PIPER-FlexPepDock protocol
(PFPD)63, and then further refined using FlexPepDock refinement (FPD)39.
UBA5 segment 370-VAYTIPKK-377 was used for docking instead of the whole
linker sequence. A shorter segment was picked under the assumption that this
region encompasses the crucial part of the interaction, and since fragment repre-
sentation as used in PFPD is more restricted for longer peptides (hence less
optimal). The UFC1-UBA5(389–404) structure was used as the receptor. The top
500 models (out of 12,500, by FPD reweighted score) were examined. Con-
formations that located the peptide within ~7 Å from UFC1 active Cys 116 and
were compatible with connection to V382 were selected for further refinement,
including both low-resolution and high-resolution steps in FPD (1000 samples).
Cavity volume estimation. Cavity volume calculation and topography mapping of
the E2 PDB structures were performed using the computed atlas of surface topo-
graphy of proteins (CASTp)40. All solvent molecules including water molecules
were removed before the calculation was made. CastP lists all the cavities present in
the protein with details of volume, area, and residues present in the cavity. The
probe radius was set at the default value of 1.4 Å for calculation. The cavities were
visualized and analyzed using PyMOL.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Atomic coordinates and structure factors were deposited in the RCSB PDB (https://
www.rcsb.org/) with the accession codes 7NW1, 7NVK, and 7NVJ for UFC1-UBA5
(389–404), UBA5(347-404)-UFC1, and UFC1(Y110A and F121A), respectively. NMR
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assignments for UFC1 were taken from the BMRB entry 6546. Previously published
crystal structures used in this study are available from the RCSB PDB under the accession
codes: 3TGD; 1J7D; 1U9A; 1×23; 1Y6L; 4Q5E; 4YII; 1Y8X; 1WZW; 6CYO; 1FZY; 1YLA;
2YBF; 2C4P; 5LBN; 3FN1; 2CYX; 2Z5D; 2F4W; 5BNB; 1YH2; 1YRV; 2Z6P; 2Z6O; 1JBB;
4Q5H; 1WZV; 3RZ3; 2DYT; 6H77. The coordinates of the structural models generated
by in silico docking are provided as Supplementary Data 1–3. Source data are provided
with this paper.
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